ClouDr Group (HKSE:09955) EBITDA Margin % : -8.57% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is ClouDr Group EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ClouDr Group's EBITDA for the six months ended in Dec. 2023 was HK$-177 Mil. ClouDr Group's Revenue for the six months ended in Dec. 2023 was HK$2,065 Mil. Therefore, ClouDr Group's EBITDA margin for the quarter that ended in Dec. 2023 was -8.57%.

ClouDr Group EBITDA Margin % Historical Data

The historical data trend for ClouDr Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClouDr Group EBITDA Margin % Chart

ClouDr Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

-104.66

-340.27

-236.00

-53.00

-5.65

ClouDr Group Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial			-153.29	-89.29	-28.21	-8.59	-8.57

Competitive Comparison of ClouDr Group's EBITDA Margin %

For the Medical Distribution subindustry, ClouDr Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ClouDr Group's EBITDA Margin % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, ClouDr Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ClouDr Group's EBITDA Margin % falls into.

ClouDr Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ClouDr Group's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-227.905	/	4036.63
	=	-5.65 %

ClouDr Group's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-176.89	/	2065.024
	=	-8.57 %

ClouDr Group (HKSE:09955) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

ClouDr Group EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ClouDr Group's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ClouDr Group (HKSE:09955) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » ClouDr Group Ltd (HKSE:09955) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

H3L:Germany

Address

No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN

Website

https://www.cloudr.cn

ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its offerings include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.

Executives

Trident Trust Company (hk) Limited	2301 Trustee
Data Vantage Development Limited	2201 Interest of corporation controlled by you
Kuang Ming	2201 Interest of corporation controlled by you
Prime Forest Assets Limited	2101 Beneficial owner
Shang Hai Qi Ji Ke Ji He Huo Qi Ye You Xian He Huo
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Zhao Yin Guo Ji Jin Rong You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si
Zhao Yin Guo Ji Jin Rong Kong Gu Shen Zhen You Xian Gong Si
Ho Chi Sing	2201 Interest of corporation controlled by you
China Merchants Bank Co., Ltd.
Zhou Quan	2201 Interest of corporation controlled by you
Idg China Venture Capital Fund Gp Iv Associates Ltd.	2201 Interest of corporation controlled by you
Haoyuan Health Limited	2101 Beneficial owner
Yass Jeffrey Steven

ClouDr Group (HKSE:09955) Headlines

No Headlines